Close Menu

MRSA

Lucigen today announced a $2.5 million grant from the National Institutes of Health to develop metagenomic DNA libraries for the identification of new antimicrobial and other anti-infective drug candidates.

Quidel recently submitted a 510(k) package to the US Food and Drug Administration for its first molecular diagnostic assay, a real-time PCR-based test for influenza A and B for use on Life Technologies' 7500 Fast Dx platform.

Citing an example of clinical applications for the MiSeq, a company representative said that one customer plans to use the instrument for MRSA testing in a hospital.

The collaboration will combine microfluidic PCR technology licensed from Caliper Life Sciences and various innovations from Canon's imaging and printing products with sample prep, digital PCR, and sequencing components from UMD researchers.

MDI's Detect-Ready MRSA panel is the only marketed PCR-based screen proven to be able to discriminate between MRSA, MSSA, and other related bacteria, the firm said.

Detect-Ready MRSA is a qualitative real-time PCR in vitro diagnostic test marketed in the European Union and Australia and in late-stage development in the US.

The company's test, called Detect-Ready, uses real-time PCR to amplify and evaluate multiple gene targets to detect and distinguish between samples containing MRSA, MSSA, and mixed populations of bacteria.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.